Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 17,304 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 17,304 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $31.00, for a total transaction of $536,424.00. Following the sale, the insider now owns 193,601 shares of the company’s stock, valued at approximately $6,001,631. This represents a 8.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael Chi also recently made the following trade(s):

• On Friday, January 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.07, for a total transaction of $174,724.13.
• On Tuesday, December 24th, Michael Chi sold 17,303 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.97, for a total value of $483,964.91.
• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $26.00, for a total transaction of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $32.25, for a total value of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $30.89 on Friday. Hims & Hers Health, Inc. has a one year low of $8.51 and a one year high of $35.02. The business’s 50-day simple moving average is $28.22 and its 200 day simple moving average is $22.17. The stock has a market cap of $6.75 billion, a price-to-earnings ratio of 70.20 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.04) EPS. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Canaccord Genuity Group increased their price objective on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. BTIG Research started coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their price target for the company from $24.00 to $25.00 in a research report on Friday, January 10th. Finally, Piper Sandler increased their price objective on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Monday, January 6th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and a consensus price target of $25.13.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HIMS. State Street Corp raised its position in shares of Hims & Hers Health by 4.7% during the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after acquiring an additional 206,078 shares in the last quarter. Geode Capital Management LLC increased its stake in Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after purchasing an additional 482,177 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after purchasing an additional 883,230 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Hims & Hers Health by 15.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after buying an additional 218,566 shares during the last quarter. Finally, Verition Fund Management LLC boosted its holdings in shares of Hims & Hers Health by 15.0% in the 3rd quarter. Verition Fund Management LLC now owns 645,731 shares of the company’s stock valued at $11,894,000 after buying an additional 84,316 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.